Cargando…

Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings

The aim of this study was to evaluate the clinical efficacy as determined by time to progression and response rate (RR) of autologous vitespen (formerly HSPPC-96; Oncophage, Antigenics Inc., New York, NY, USA) with and without interleukin-2 (IL-2; Proleukin: Chiron, Emoryville, CA, USA) in stage IV...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jonasch, E, Wood, C, Tamboli, P, Pagliaro, L C, Tu, S M, Kim, J, Srivastava, P, Perez, C, Isakov, L, Tannir, N
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361701/ https://www.ncbi.nlm.nih.gov/pubmed/18362942 http://dx.doi.org/10.1038/sj.bjc.6604266

Ejemplares similares

Response to post-axitinib treatment in patients with metastatic renal cell carcinoma
por: Chittoria, Namita, et al.
Publicado: (2016)

P02.21. Short- and long-term effects of expressive writing in patients with renal cell carcinoma
por: Cohen, L, et al.
Publicado: (2012)

High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma
por: Ho, T H, et al.
Publicado: (2016)

Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma
por: Lotem, M, et al.
Publicado: (2004)

The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma
por: Ho, Thai H, et al.
Publicado: (2015)

Contemporary approach to diagnosis and classification of renal cell carcinoma with mixed histologic features
por: Sircar, Kanishka, et al.
Publicado: (2013)

Autologous tumor lysate-loaded dendritic cell vaccination combined with Sunitinib for metastatic renal cell carcinoma
por: Kakimi, Kazuhiro, et al.
Publicado: (2014)

Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non‐sarcomatoid renal carcinomas
por: Sircar, Kanishka, et al.
Publicado: (2015)

Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell Carcinoma
por: Pilié, Patrick G., et al.
Publicado: (2017)

Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma
por: Msaouel, Pavlos, et al.
Publicado: (2017)

Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma
por: Campbell, Matthew T., et al.
Publicado: (2021)

A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma
por: Matsushita, Hirokazu, et al.
Publicado: (2014)

Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy
por: Shapiro, Daniel D., et al.
Publicado: (2023)

Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses
por: Dillman, Robert O., et al.
Publicado: (2018)

Evaluation of an autologous cancer vaccine for the treatment of metastatic canine hemangiosarcoma: a preliminary study
por: Lucroy, Michael D., et al.
Publicado: (2020)

Depressive Symptoms and Cortisol Rhythmicity Predict Survival in Patients with Renal Cell Carcinoma: Role of Inflammatory Signaling
por: Cohen, Lorenzo, et al.
Publicado: (2012)

Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials
por: Hahn, Andrew W, et al.
Publicado: (2020)

Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma
por: Dillman, Robert O, et al.
Publicado: (2019)

Carcinoembryonic antigen (CEA) expression and heterogeneity in primary and autologous metastatic gastric tumours demonstrated by a monoclonal antibody.
por: Hockey, M. S., et al.
Publicado: (1984)

Intratumoral Morphologic and Molecular Heterogeneity of Rhabdoid Renal Cell Carcinoma: Challenges for Personalized Therapy
por: Singh, Rajesh R., et al.
Publicado: (2015)

Portrait of an autologous cancer vaccine: Then and now
por: Berd, David
Publicado: (2023)

Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib
por: Mohammad, H., et al.
Publicado: (2021)

Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours
por: Nicol, A J, et al.
Publicado: (2011)

Brain metastasis in renal cancer patients: metastatic pattern, tumour-associated macrophages and chemokine/chemoreceptor expression
por: Wyler, L, et al.
Publicado: (2014)

Safety and efficacy of autologous tumour cell vaccines as a cancer therapeutic to treat solid tumours and haematological malignancies: a meta-analysis protocol for two systematic reviews
por: Khan, Sarwat T, et al.
Publicado: (2020)

Nonrandomised controlled trial in recurrent glioblastoma patients: the promise of autologous tumour lysate-loaded dendritic cell vaccination
por: Pasqualetti, Francesco, et al.
Publicado: (2023)

In vivo fluorescence kinetics and localisation of aluminum phthalocyanine disulphonate in an autologous tumour model.
por: Witjes, M. J., et al.
Publicado: (1996)

The Safety of an Adjuvanted Autologous Cancer Vaccine Platform in Canine Cancer Patients
por: Weir, Chris, et al.
Publicado: (2018)

Streptozotocin-induced renal tumours in rats.
por: Horton, L., et al.
Publicado: (1977)

Cadherin-11 in Renal Cell Carcinoma Bone Metastasis
por: Satcher, Robert L., et al.
Publicado: (2014)

Measurements of metastatic renal cell tumours as determined by diffusion weighted imaging or computed tomography are in close agreement, a pilot study
por: Farnebo, J., et al.
Publicado: (2017)

Combination antiangiogenic tyrosine kinase inhibition and anti‐PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes
por: Laccetti, Andrew L., et al.
Publicado: (2021)

HIV transmitted/founder vaccines elicit autologous tier 2 neutralizing antibodies for the CD4 binding site
por: McCurley, Nathanael P., et al.
Publicado: (2017)

Differential Expression of Prognostic Proteomic Markers in Primary Tumour, Venous Tumour Thrombus and Metastatic Renal Cell Cancer Tissue and Correlation with Patient Outcome
por: Laird, Alexander, et al.
Publicado: (2013)

Antibody responses in furunculosis patients vaccinated with autologous formalin-killed Staphylococcus aureus
por: Holtfreter, S., et al.
Publicado: (2011)

Complete remission of chemo‐refractory multiple‐metastatic upper tract urothelial carcinoma by autologous formalin‐fixed tumor vaccine
por: Miyoshi, Tatsu, et al.
Publicado: (2017)

Real-World Experience With Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis
por: Lemke, Emily A., et al.
Publicado: (2019)

Tumor heterogeneity as a rationale for a multi-epitope approach in an autologous renal cell cancer tumor vaccine
por: Wittke, Stefan, et al.
Publicado: (2016)

Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma
por: Wiele, Andrew J., et al.
Publicado: (2021)

Relationship of hypoxia to metastatic ability in rodent tumours
por: Jaeger, K De, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_gd9k8592g72lfskov8jkethuoj